DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the stock.

DBVT has been the topic of several other reports. HC Wainwright increased their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a "buy" rating in a research note on Thursday, October 24th. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Stock Performance

DBVT stock traded down $0.03 on Thursday, hitting $0.59. 34,514 shares of the company's stock were exchanged, compared to its average volume of 230,674. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.14. The stock has a market cap of $56.56 million, a P/E ratio of -0.69 and a beta of 0.66. The firm has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $0.89.

DBV Technologies shares are going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,568,909 shares of the company's stock after buying an additional 327,345 shares during the period. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.'s holdings, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.